침습 유방암 환자의 HER2 유전자 증폭 검사를 위한 미세침흡인물의 유용성

참고문헌 (31)

1. Ross JS, "The HER2-neu gene and protein in breast cancer 2003: biomarker and target of therapy", Oncologist, 8, pp.307~325 (2003)
2. Ross JS, "The HER-2", neu oncogene: prognostic factor, predictive factor and target for therapy, 1999, pp.9, 125~138
3. Toikkanen S, "Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-years followup", J Clin Oncol, 10, pp.1044~1048 (1992)
4. Konecny G, "Quantitative association between HER-2", neu and steroid hormone receptors in hormone receptor-positive primary breast cancer, 2003, pp.95, 142~153
5. Son GM, "mutation and cerbB2 over-expression in predicting factor of responsibility to neoadjuvant chemotherapy in patients with breast cancer", J Korean Surg Soc, 65, pp.85~94 (2003)
6. Nahta R, "Trastuzumab: triumphs and tribulations", Oncogene, 26, pp.3637~3643 (2007)
7. Baselga J, "Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer", Oncologist, 11, pp.4~12 (2006)
8. Piccart-Gebhart MJ, "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer", N Engl J Med, 353, pp.1659~1672 (2005)
9. Bast RC Jr., "2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology", J Clin Oncol, 19, pp.1865~1878 (2001)
10. Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.25, 118~145
11. Press MF, "Sensitivity of HER- 2", neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression, 1994, pp.54, 2771~2777
12. Jacobs TW, "Specificity of HercepTest in determining HER-2", neu status of breast cancers using the United States Food and Drug Administration-approved scoring system, 1999, pp.17, 1983~1987
13. 박경미, "유방암종의 HER-2", neu검색을 위한 형광제자리부합화와 면역조직화학 염색법의 비교, 2002, pp.36(4), 243~248[DOI]
14. Pauletti G, "Assessment of methods for tissue-based detection of the HER-2", neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry, 2000, pp.18, 3651~3664
15. Sidoni A, "Detection of HER-2", neu (c-erbB-2) overexpression and amplification in breast carcinomas with ambiguous immunohistochemical results. A further contribution to defining the role of fluorescent in situ hybridization, 2006, pp.26, 2333~2337
16. Dybdal N, "Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab", Breast Cancer Res Treat, 93, pp.3~11 (2005)
17. Roche PC, "Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831", J Natl Cancer Inst, 94, pp.855~857 (2002)
18. Paik S, "Realworld performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience", J Natl Cancer Inst, 944, pp.852~85 (2002)
19. Perez EA, "HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial", J Clin Oncol, 24(2), pp.3032~3038 (2006)
20. Beatty BG, "Gibson PC, Leiman G, et al. HER-2", neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis, 2004, pp.122, 246~255
21. Gu M, "Fluorescence in situ hybridization for HER-2", neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens, 2005, pp.19, 471~476
22. Bozzetti C, "HER-2", neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma, 2003, pp.99, 310~315
23. Tsukamoto F, "Detection of chromosomal aneusomy by fluorescence in situ hybridization in fine-needle aspirates from breast tumors: application to the preoperative diagnosis of breast carcinoma", Cancer, 90, pp.373~378 (2000)
24. Tsuda H, "HER-2 (c-erbB-2) test update: present status and problems", Breast Cancer, 13, pp.236~248 (2006)
25. Bozzetti C, "HER-2", neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer, 2002, pp.13, 1398~1403
26. Sauter G, "Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies", Acta Cytol, 40, pp.164~173 (1996)
27. Mezzelani A, "c-erbB2", neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates, 1999, pp.80, 519~525
28. Nizzoli R, "Immunocytochemical evaluation of HER-2", neu on fine-needle aspirates from primary breast carcinomas, 2003, pp.28, 142~146
29. McManus DT, "Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates", Mol Pathol, 52, pp.75~77 (1999)
30. Nizzoli R, "HER-2", neu evaluation by fluorescence in situ hybridization on destained cytologic smears from primary and metastatic breast cancer, 2005, pp.49, 27~30
31. Latta EK, "The role of HER2", neu overexpression, Mod Pathol, pp.2002[DOI]

관련 논문AI추천